article thumbnail

Reinventing the small molecule toolbox: from proteins to RNA

Dark Matter Blog

The bulk of my nearly three decades of experience up to that point was with drugging protein targets using a variety of modalities, but principally small molecules. The post Reinventing the small molecule toolbox: from proteins to RNA appeared first on Arrakis Therapeutics. Welcome to the RNA world.

article thumbnail

Condensate biology: advancing drug discovery for complex diseases

Drug Target Review

The aim is to establish condensate biology as a fundamental branch of cell biology – “cell biology 2.0” The underlying biology and processes upon which the company was founded have broad applicability across various human disease areas. Klein notes the importance of Dewpoint’s disease-agnostic approach.

Disease 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Women in STEM with Juliet Williams

Drug Target Review

Shortly after finishing my studies, I landed my first job in industry working on cell biology research for several disease indications. Now we’re focusing on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with immunology conditions.

article thumbnail

New molecular insights on medical cannabis

Drug Target Review

Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. The Journal of Cell Biology. Structure–Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode. Umezu-Goto M, Kishi Y, Taira A, et al. 2017;2017:1–15.

article thumbnail

Scientists uncover a new approach for treating aggressive cancer

The Pharma Data

They then developed a new therapeutic approach with a potent small-molecule inhibitor of this enzyme. Certain subtypes of blood cancers such as acute leukemias rely on multiple mechanisms for sustaining growth of aggressive cancer cells. Their findings are published online in Nature Cell Biology.

article thumbnail

The future of mRNA biology and AI convergence

Drug Target Review

mRNA biology has become widely recognised as a new “drug mine” RNAi drugs are in the market and mRNA vaccines, initially developed for Covid-19, are already in trials for cancer. All of these are novel targets to be explored in small molecule drug discovery as well as for improving the efficacy of mRNA vaccines.

Disease 105
article thumbnail

Fighting Parasitic Infections: Promise in Cyclic Peptides

NIH Director's Blog: Drug Discovery

Researchers soon began screening a chemical library and its more than 380,000 traditional drug candidates to find the right small-molecule inhibitor, the preferred compound in drug discovery. Missing was the usual pocket-shaped active site, where a traditional small molecule can readily bind and block function.